Gastric Cancer: Phase 3 | The efficacy of fluorouracil/thiopiperidine in the treatment of metastatic gastroesophageal junction cancer

The survival prognosis of patients with advanced gastroesophageal junction cancer (GEJC) is poor; there is currently a lack of clinical trial data specific to GEJC, and most of the existing data are derived fromThe overall evaluation of gastric cancer (GC) treatment drugs.

This article reports the results of a subgroup analysis of the primary tumor type (GC or GEJC) in the TAGS trial.

The TAGS trial recruited mGC or mGEJC patients who had previously been treated with 2-line or above chemotherapy, and were randomized (2:1) to receive FTD/TPI or placebo treatment, while giving the best supportive treatment.

Baseline characteristics of the patient

A total of 507 patients were recruited, including 145 (29%) GEJC and 360 (71%) GC.

Efficacy prognosis in GEJC and GC groups

The survival benefit of FTD/TPI treatment was observed in both subgroups.

Time before deterioration

In the GEJC and GC subgroups, 75 patients (77%) and 192 patients (81%) who received FTD/TPI treatment, respectively, reported adverse events ≥ Grade 3 caused by any cause.

In summary, in the TAGS trial, as in GC patients, FTD/TPI also showed efficacy advantages and controllable safety in GEJC patients.

Mansoor, W.